My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 816

    1.

    Factor V Leiden mutation and the risks for thromboembolic disease: a clinical perspective.

    Price DT, Ridker PM.

    Ann Intern Med. 1997 Nov 15;127(10):895-903. Review.PMID: 9382368 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Activated protein C resistance--a major risk factor for thrombosis.

    Rosén SB, Sturk A.

    Eur J Clin Chem Clin Biochem. 1997 Jul;35(7):501-16. Review.PMID: 9263726 [PubMed - indexed for MEDLINE]Related articles

    3.

    Selective screening for the Factor V Leiden mutation: is it advisable prior to the prescription of oral contraceptives?

    Schambeck CM, Schwender S, Haubitz I, Geisen UE, Grossmann RE, Keller F.

    Thromb Haemost. 1997 Dec;78(6):1480-3.PMID: 9423798 [PubMed - indexed for MEDLINE]Related articles

    4.

    Activated protein C resistance and factor V Leiden mutation are independent risk factors for venous thromboembolism.

    Rodeghiero F, Tosetto A.

    Ann Intern Med. 1999 Apr 20;130(8):643-50.PMID: 10215560 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    Effects of oral contraceptives on hemostasis and thrombosis.

    Rosing J, Tans G.

    Am J Obstet Gynecol. 1999 Jun;180(6 Pt 2):S375-82. Review.PMID: 10368524 [PubMed - indexed for MEDLINE]Related articles

    6.

    Effect of exogenous estrogen on atherothrombotic vascular disease risk related to the presence or absence of the factor V Leiden mutation (resistance to activated protein C).

    Glueck CJ, Wang P, Fontaine RN, Tracy T, Sieve-Smith L, Lang JE.

    Am J Cardiol. 1999 Sep 1;84(5):549-54.PMID: 10482153 [PubMed - indexed for MEDLINE]Related articles

    7.

    Resistance to activated protein C, highly prevalent amongst users of oral contraceptives with venous thromboembolism.

    Bennet L, Odeberg H.

    J Intern Med. 1998 Jul;244(1):27-32.PMID: 9698021 [PubMed - indexed for MEDLINE]Related articles

    8.

    Resistance to activated protein C in women using oral contraceptives.

    Spannagl M, Dick A, Assmann A, Heinemann L, Schramm W.

    Semin Thromb Hemost. 1998;24(5):423-30.PMID: 9834008 [PubMed - indexed for MEDLINE]Related articles

    9.

    Screening for thrombophilia in high-risk situations: systematic review and cost-effectiveness analysis. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) study.

    Wu O, Robertson L, Twaddle S, Lowe GD, Clark P, Greaves M, Walker ID, Langhorne P, Brenkel I, Regan L, Greer I.

    Health Technol Assess. 2006 Apr;10(11):1-110. Review.PMID: 16595080 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    Normalized activated protein C ratio itself not associated with increased risk of venous thromboembolism.

    Heinemann LA, Assmann A, Spannagl M, Schramm W, Dick A, Kluft C, de Maat MP.

    Contraception. 1998 Nov;58(5):321-2.PMID: 9883389 [PubMed - indexed for MEDLINE]Related articles

    11.

    Resistance to activated protein C--frequent etiologic factor for venous thrombosis.

    Simkova M, Simko F, Kovacs L.

    Bratisl Lek Listy. 2001;102(5):240-7. Review.PMID: 11725376 [PubMed - indexed for MEDLINE]Related articles

    12.

    Resistance to activated protein C as a basis for venous thromboembolism associated with pregnancy and oral contraceptives.

    Hellgren M, Svensson PJ, Dahlbäck B.

    Am J Obstet Gynecol. 1995 Jul;173(1):210-3.PMID: 7631684 [PubMed - indexed for MEDLINE]Related articles

    13.

    Oral contraceptives enhance the risk of clinical manifestation of venous thrombosis at a young age in females homozygous for factor V Leiden.

    Rintelen C, Mannhalter C, Ireland H, Lane DA, Knöbl P, Lechner K, Pabinger I.

    Br J Haematol. 1996 May;93(2):487-90.PMID: 8639453 [PubMed - indexed for MEDLINE]Related articles

    14.

    Epidemiology of factor V Leiden: clinical implications.

    De Stefano V, Chiusolo P, Paciaroni K, Leone G.

    Semin Thromb Hemost. 1998;24(4):367-79. Review.PMID: 9763354 [PubMed - indexed for MEDLINE]Related articles

    15.

    Probability of recurrence of thrombosis in patients with and without factor V Leiden.

    Rintelen C, Pabinger I, Knöbl P, Lechner K, Mannhalter C.

    Thromb Haemost. 1996 Feb;75(2):229-32.PMID: 8815565 [PubMed - indexed for MEDLINE]Related articles

    16.

    The risk of recurrent venous thromboembolism in patients with an Arg506-->Gln mutation in the gene for factor V (factor V Leiden).

    Simioni P, Prandoni P, Lensing AW, Scudeller A, Sardella C, Prins MH, Villalta S, Dazzi F, Girolami A.

    N Engl J Med. 1997 Feb 6;336(6):399-403.PMID: 9010145 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    Resistance to activated protein C (APC): mutation at Arg506 of coagulation factor V and vascular access thrombosis in haemodialysis patients.

    Födinger M, Mannhalter C, Pabinger I, Koizar D, Rintelen C, Hörl WH, Sunder-Plassmann G.

    Nephrol Dial Transplant. 1996 Apr;11(4):668-72.PMID: 8671856 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    Activated protein C resistance, the factor V Leiden mutation, and a laboratory testing algorithm.

    Van Cott EM, Soderberg BL, Laposata M.

    Arch Pathol Lab Med. 2002 May;126(5):577-82. Review.PMID: 11958664 [PubMed - indexed for MEDLINE]Related articles

    19.

    Are factor V Leiden carriers who use oral contraceptives at extreme risk for venous thromboembolism?

    Spannagl M, Heinemann LA, Schramm W.

    Eur J Contracept Reprod Health Care. 2000 Jun;5(2):105-12.PMID: 10943572 [PubMed - indexed for MEDLINE]Related articles

    20.

    Factor V Leiden: should we screen oral contraceptive users and pregnant women?

    Vandenbroucke JP, van der Meer FJ, Helmerhorst FM, Rosendaal FR.

    BMJ. 1996 Nov 2;313(7065):1127-30. Review.PMID: 8916702 [PubMed - indexed for MEDLINE]Related articlesFree article

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity